Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reverse engineering of motor unit discharge in multiple sclerosis reveals heterogeneity of voluntary motor commands.

medRxiv : the preprint server for health sciences·2026
Same author

A novel methodological framework for the assessment of the neural control of the shoulder using high-density surface electromyography.

Methods (San Diego, Calif.)·2026
Same author

The increase in time to task failure following endurance training is associated with adjustments in motor unit firing properties.

Journal of applied physiology (Bethesda, Md. : 1985)·2026
Same author

Effect of intensive care unit hospitalization for acute respiratory distress syndrome on strength, fatigue and motor unit behaviour.

Scientific reports·2026
Same author

Differential changes in the effective neural drive following new motor skill acquisition between vastus lateralis and medialis.

European journal of applied physiology·2026
Same author

Implementing sustainable liver health in Europe: a second EASL-Lancet Commission.

Lancet (London, England)·2026

Related Experiment Video

Updated: May 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Does telaprevir possess a direct antidiabetic effect?

Paulino Tallón de Lara1, Thomas Himschoot, Jean-Louis Frossard

  • 1Division of Gastroenterology and Hepatology, University Hospitals, Geneva 4, Switzerland.

Liver International : Official Journal of the International Association for the Study of the Liver
|December 17, 2013
PubMed
Summary
This summary is machine-generated.

Telaprevir, an effective Hepatitis C virus (HCV) treatment, may also possess independent antidiabetic properties. This case study suggests telaprevir could lower glucose levels, warranting further investigation into its potential as an antidiabetic agent.

Keywords:
hepatitis Cinsulin resistanceprotease inhibitortype 2 diabetes

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K
Cellular Redox Profiling Using High-content Microscopy
11:37

Cellular Redox Profiling Using High-content Microscopy

Published on: May 14, 2017

10.4K

Related Experiment Videos

Last Updated: May 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K
Cellular Redox Profiling Using High-content Microscopy
11:37

Cellular Redox Profiling Using High-content Microscopy

Published on: May 14, 2017

10.4K

Area of Science:

  • Hepatology
  • Endocrinology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is linked to insulin resistance, which typically improves after viral clearance.
  • Telaprevir is a protease inhibitor used to treat HCV genotype 1.
  • Insulin resistance and type 2 diabetes are common comorbidities in HCV patients.

Observation:

  • A patient with type 2 diabetes and HCV received triple therapy including telaprevir.
  • The patient experienced a significant drop in glucose levels and hypoglycemia shortly after starting telaprevir, necessitating discontinuation of her diabetes medications.
  • Despite achieving sustained virologic response (SVR) and remaining aviremic, her diabetes worsened after telaprevir treatment cessation.

Findings:

  • Telaprevir treatment was associated with a marked reduction in blood glucose levels and episodes of hypoglycemia.
  • The antidiabetic effect appeared independent of HCV viral load suppression, as glucose control deteriorated upon telaprevir withdrawal despite ongoing SVR.
  • The patient required resumption of her previous antidiabetic regimen after completing telaprevir therapy.

Implications:

  • Telaprevir may possess a direct antidiabetic effect beyond its antiviral activity.
  • Further research is needed to elucidate the mechanisms behind telaprevir's potential glucose-lowering properties.
  • This finding could open new therapeutic avenues for managing diabetes in HCV patients or exploring telaprevir for diabetes treatment.